was read the article
array:21 [ "pii" => "X2013251412001019" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Feb.11374" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:136-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4860 "formatos" => array:3 [ "EPUB" => 269 "HTML" => 3889 "PDF" => 702 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512001011" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2012.Feb.11374" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:136-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 9313 "formatos" => array:3 [ "EPUB" => 280 "HTML" => 8452 "PDF" => 581 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Nefritis lúpica: en busca de un futuro mejor" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "136" "paginaFinal" => "138" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Lupus nephritis: in search of a better future" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Á. Frutos, Manuel Praga, Carlos Quereda, Francisco Rivera, Alfons Segarra" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Miguel Á." "apellidos" => "Frutos" ] 1 => array:2 [ "nombre" => "Manuel" "apellidos" => "Praga" ] 2 => array:2 [ "nombre" => "Carlos" "apellidos" => "Quereda" ] 3 => array:2 [ "nombre" => "Francisco" "apellidos" => "Rivera" ] 4 => array:2 [ "nombre" => "Alfons" "apellidos" => "Segarra" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412001019" "doi" => "10.3265/Nefrologia.pre2012.Feb.11374" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412001019?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512001011?idApp=UINPBA000064" "url" => "/02116995/0000003200000002/v0_201502091353/X0211699512001011/v0_201502091353/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X201325141200099X" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Nov.11066" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:139-42" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5359 "formatos" => array:3 [ "EPUB" => 291 "HTML" => 4361 "PDF" => 707 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Intraperitoneal administration of daptomycin in recurrent peritonitis with suspected biofilm" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "139" "paginaFinal" => "142" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Administración intraperitoneal de daptomicina en peritonitis recurrente con sospecha de biofilm" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Laura García-López, M. José Fernández-Reyes Luis, M. Teresa Criado-Illana, Leonor Gómez-Sayago, Manuel Heras-Benito" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Laura" "apellidos" => "García-López" ] 1 => array:2 [ "nombre" => "M. José" "apellidos" => "Fernández-Reyes Luis" ] 2 => array:2 [ "nombre" => "M. Teresa" "apellidos" => "Criado-Illana" ] 3 => array:2 [ "nombre" => "Leonor" "apellidos" => "Gómez-Sayago" ] 4 => array:2 [ "nombre" => "Manuel" "apellidos" => "Heras-Benito" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000992" "doi" => "10.3265/Nefrologia.pre2011.Nov.11066" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000992?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141200099X?idApp=UINPBA000064" "url" => "/20132514/0000003200000002/v0_201502091616/X201325141200099X/v0_201502091616/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251412001027" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Jan.11310" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:133-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8463 "formatos" => array:3 [ "EPUB" => 302 "HTML" => 7134 "PDF" => 1027 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "The electrical basis of bioimpedance" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "133" "paginaFinal" => "135" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Fundamentos eléctricos de la bioimpedancia" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11310_16025_28456_en_f1_11310.jpg" "Alto" => 1395 "Ancho" => 1051 "Tamanyo" => 305944 ] ] "descripcion" => array:1 [ "en" => "Voltage and current in alternating current circuits" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Andrés Sánchez-Iglesias, Milagros Fernández-Lucas, José L. Teruel" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Andrés" "apellidos" => "Sánchez-Iglesias" ] 1 => array:2 [ "nombre" => "Milagros" "apellidos" => "Fernández-Lucas" ] 2 => array:2 [ "nombre" => "José L." "apellidos" => "Teruel" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X021169951200102X" "doi" => "10.3265/Nefrologia.pre2012.Jan.11310" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169951200102X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412001027?idApp=UINPBA000064" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412001027/v0_201502091616/en/main.assets" ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Lupus nephritis: in search of a better future" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "136" "paginaFinal" => "138" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Miguel Á. Frutos, Manuel Praga, Carlos Quereda, Francisco Rivera, Alfons Segarra" "autores" => array:5 [ 0 => array:4 [ "nombre" => "Miguel Á." "apellidos" => "Frutos" "email" => array:1 [ 0 => "mangel.frutos.sspa@juntadeandalucia.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "Manuel" "apellidos" => "Praga" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "Carlos" "apellidos" => "Quereda" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 3 => array:3 [ "nombre" => "Francisco" "apellidos" => "Rivera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] ] ] 4 => array:3 [ "nombre" => "Alfons" "apellidos" => "Segarra" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "affe" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Servicio de Nefrología, Cochrane Renal Group. Grupo de MBE de la SEN. Hospital Universitario Ramón y Cajal, Madrid, " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] 3 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital General Universitario de Ciudad Real, Ciudad Real, " "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "affd" ] 4 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Universitari Vall d'Hebron, Barcelona, " "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "affe" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nefritis lúpica: en busca de un futuro mejor" ] ] "textoCompleto" => "<p class="elsevierStylePara">The Spanish Society of Nephrology and the Spanish Society of Internal Medicine recently presented a consensus document for the diagnosis and treatment of lupus nephritis,<span class="elsevierStyleSup">1</span> which was intended to facilitate diagnostic and therapeutic decision-making regarding patients with systemic lupus erythematosus (SLE) and altered renal function.</p><p class="elsevierStylePara">This document, composed of five chapters and based on an exhaustive literature review, summarises a list of recommendations that brings current knowledge on the subject up to date and provides support, with various levels of evidence, for important decisions in the clinical care of lupus nephritis patients.</p><p class="elsevierStylePara">The collaboration between these two scientific societies was based on solid multidisciplinary foundations that must be considered for these patients with chronic diseases, from the initial stages of diagnosing and evaluating the type of renal damage, choosing the proper treatment, and monitoring. The essential objectives are to identify problems as early as possible and that can be prevented or treated as effectively as possible in order to achieve the highest level of remission for as long as possible.</p><p class="elsevierStylePara">Several studies have been published in recent decades that have provided new and sometimes highly awaited and important pieces of evidence that have facilitated a personalised and effective treatment of patients with lupus nephritis, with fewer complications. This new panorama is driving important advancements in the quality and quantity of life of these patients by improving the control of the immunological activity of SLE and the recovery of deteriorated renal function.</p><p class="elsevierStylePara">Renal involvement occurs in half of all patients with SLE, and plays a very important role in this disease, since it independently affects patient survival. Therefore, evaluating proteinuria, urinary sediment, and glomerular filtration rate must all be prioritised in patients with SLE, both in the initial doctor’s visit and in subsequent check-ups. Additionally, a renal biopsy performed following established recommendations guarantees a precise evaluation of the type and extent of the renal damage, justifying the choice of procedures that are not without risk. The decision of which treatment to choose among the possible alternatives listed in the guidelines must be supported by individual clinical and pathological characteristics, keeping in mind that the patient must not be under-treated (greater risk of irreversible organ damage) or over-treated (more complications and greater severity).</p><p class="elsevierStylePara">We have recently been able to understand some of the mechanisms involved in the development of lupus nephritis in the context of hyperactive B lymphocytes, caused by an altered Lyn protein that usually regulates the activation of these B-cells. Among the culprits are basophils and mast cells, two of the cell lineages related to the pathogenesis that involves Th2 lymphocytes.<span class="elsevierStyleSup">2</span> These are major advancements in determining the origin of the disease and identifying therapeutic targets.</p><p class="elsevierStylePara">As one of the most notable milestones in the treatment of lupus nephritis, we must mention cyclophosphamide pulses along with steroids. The widespread use of this treatment allowed for reaching a higher rate of remission, both of lupus disease in general and renal damage in particular. Currently, any treatment that might act as an alternative to cyclophosphamide must first prove that it does not have inferior potency or efficacy and that it can provide additional advantages to cyclophosphamide, at least in three of the areas where we still need to make progress: adverse effects, recurrence, and unresponsive patients. Although we have reached high levels of remission using cyclophosphamide, the price of the treatment and the rates of recurrence are very high and oblige us to maintain patients on immunosuppressants for long periods of time, sometimes lifelong.</p><p class="elsevierStylePara">Fortunately, several well designed studies with control groups have produced therapeutic advancements in this field. Firstly, the discovery that induction doses of cyclophosphamide during shorter time periods were capable of achieving the same efficacy, even at lower doses,<span class="elsevierStyleSup">3,4</span> which opened the door for more recent developments. This yielded mycophenolate (a “friendly” drug following successes in kidney transplants) as an alternative to cyclophosphamide, both in induction<span class="elsevierStyleSup">5</span> and maintenance<span class="elsevierStyleSup">6,7 </span>phases, for the majority of patients with lupus nephritis. It offers some advantages over azathioprine in efficacy, interval between recurrences, and time to salvage therapy.</p><p class="elsevierStylePara">In the chapter on resistance to cyclophosphamide and mycophenolate, the guidelines describe where a repeated renal biopsy might be performed to search for changes and where administering immunosuppression along with triple therapy. It also underscores that some patients may respond well to lymphocyte-depleting biological agents, calcineurin inhibitors, or immunoglobulins, where evidence in support is still not so well established. In these situations, the recommendations are still a source of controversy, probably due to the heterogeneity of clinical presentations and several other factors that may influence the disparity in patient responses.</p><p class="elsevierStylePara">When the experience gained in treating patients with lupus nephritis is measured in decades instead of years, certain precautions take on much greater importance. In this sense, the guidelines clearly take into account the current policy of steroid saving, a strategy that must always influence our therapeutic recommendations since, once reaching the chronic stage of the disease, we must imagine the patient after 20 or more years of treatment. Along this same line, concomitant treatment with anti-proteinuria drugs has gained major importance, especially in patients with resistant or residual proteinuria, which we now know is never innocuous, and the lower, the better. If we only consider the kidney and its alterations, we lose perspective and objectivity regarding protection against cardiovascular risk and bone damage, hindering an overall therapeutic approach to patients with SLE. Whenever possible, we should take a multidisciplinary approach to treatment, since this type of collaboration provides major advantages in disease prevention (arteriosclerosis, prophylaxis against infections, and bone and joint complications) and under certain circumstances (renal failure, gestation, and anti-phospholipid syndrome), even in patients with apparently good levels of remission of nephritis and SLE.</p><p class="elsevierStylePara">The consensus document also includes a number of recommendations for special situations, including actions to take in advanced stages of chronic kidney disease and possibilities for renal replacement therapy, which will be needed in almost 20% of all patients with lupus nephritis,<span class="elsevierStyleSup">8</span> a complication that currently does not prevent reaching good results with different dialysis treatments or kidney transplant.<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">When we speak of the future, we always imagine new drugs that will be better at treating lupus nephritis, and without a doubt, this is the most promising avenue for development. This is the field where we have experienced the greatest progress in the past and so should it be in the future, although we must keep in mind already existing drugs, such as anti-malarial medications, which are now employed as concomitant treatments. The drugs that will constitute the future therapeutic arsenal against lupus nephritis will be much closer to the ideal, since they will focus on specific targets and produce fewer side effects. These treatments will be adjusted for each individual and level of renal involvement. With the aid of biological markers, we will be able to better determine the severity of the disease and response to treatment than using proteinuria levels, urinary sediment, and creatinine clearance. We will also be able to better distinguish between a flare of lupus activity and other non-immunological processes that involve organ damage. Although this currently seems like a complicated task, it is close to being a reality.</p><p class="elsevierStylePara">With these ambitious objectives, the SEMI-SEN guidelines for the diagnosis and treatment of lupus nephritis should provide a useful tool that facilitates decision- making, supported by the best evidence currently available, with idea that the present and future condition of patients with lupus nephritis can be undoubtedly better.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The authors affirm that they have no conflicts of interest related to the content of this article.</p>" "pdfFichero" => "P1-E534-S3440-A11374-EN.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412001019/v0_201502091616/en/main.assets" "Apartado" => array:4 [ "identificador" => "35428" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial Comments" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000002/v0_201502091616/X2013251412001019/v0_201502091616/en/P1-E534-S3440-A11374-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412001019?idApp=UINPBA000064" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 4 | 5 | 9 |
2024 October | 39 | 35 | 74 |
2024 September | 55 | 29 | 84 |
2024 August | 58 | 59 | 117 |
2024 July | 37 | 70 | 107 |
2024 June | 51 | 32 | 83 |
2024 May | 43 | 34 | 77 |
2024 April | 42 | 37 | 79 |
2024 March | 27 | 19 | 46 |
2024 February | 21 | 28 | 49 |
2024 January | 26 | 27 | 53 |
2023 December | 26 | 21 | 47 |
2023 November | 42 | 34 | 76 |
2023 October | 69 | 44 | 113 |
2023 September | 84 | 29 | 113 |
2023 August | 69 | 16 | 85 |
2023 July | 31 | 32 | 63 |
2023 June | 30 | 19 | 49 |
2023 May | 40 | 32 | 72 |
2023 April | 39 | 12 | 51 |
2023 March | 53 | 19 | 72 |
2023 February | 32 | 18 | 50 |
2023 January | 28 | 30 | 58 |
2022 December | 33 | 31 | 64 |
2022 November | 42 | 31 | 73 |
2022 October | 34 | 39 | 73 |
2022 September | 30 | 26 | 56 |
2022 August | 43 | 35 | 78 |
2022 July | 19 | 43 | 62 |
2022 June | 39 | 32 | 71 |
2022 May | 25 | 27 | 52 |
2022 April | 29 | 43 | 72 |
2022 March | 40 | 37 | 77 |
2022 February | 28 | 47 | 75 |
2022 January | 31 | 24 | 55 |
2021 December | 34 | 33 | 67 |
2021 November | 25 | 34 | 59 |
2021 October | 30 | 36 | 66 |
2021 September | 21 | 30 | 51 |
2021 August | 21 | 39 | 60 |
2021 July | 29 | 25 | 54 |
2021 June | 22 | 18 | 40 |
2021 May | 25 | 23 | 48 |
2021 April | 62 | 54 | 116 |
2021 March | 43 | 31 | 74 |
2021 February | 22 | 19 | 41 |
2021 January | 17 | 16 | 33 |
2020 December | 20 | 14 | 34 |
2020 November | 27 | 6 | 33 |
2020 October | 21 | 12 | 33 |
2020 September | 8 | 5 | 13 |
2020 August | 30 | 11 | 41 |
2020 July | 24 | 6 | 30 |
2020 June | 24 | 10 | 34 |
2020 May | 18 | 9 | 27 |
2020 April | 20 | 20 | 40 |
2020 March | 26 | 8 | 34 |
2020 February | 30 | 19 | 49 |
2020 January | 31 | 15 | 46 |
2019 December | 26 | 20 | 46 |
2019 November | 29 | 12 | 41 |
2019 October | 17 | 7 | 24 |
2019 September | 19 | 27 | 46 |
2019 August | 15 | 16 | 31 |
2019 July | 23 | 17 | 40 |
2019 June | 22 | 9 | 31 |
2019 May | 20 | 10 | 30 |
2019 April | 46 | 26 | 72 |
2019 March | 33 | 19 | 52 |
2019 February | 19 | 21 | 40 |
2019 January | 21 | 17 | 38 |
2018 December | 82 | 39 | 121 |
2018 November | 144 | 20 | 164 |
2018 October | 149 | 20 | 169 |
2018 September | 71 | 14 | 85 |
2018 August | 103 | 15 | 118 |
2018 July | 65 | 19 | 84 |
2018 June | 58 | 9 | 67 |
2018 May | 71 | 18 | 89 |
2018 April | 75 | 15 | 90 |
2018 March | 71 | 12 | 83 |
2018 February | 89 | 13 | 102 |
2018 January | 70 | 13 | 83 |
2017 December | 58 | 13 | 71 |
2017 November | 45 | 9 | 54 |
2017 October | 36 | 9 | 45 |
2017 September | 32 | 14 | 46 |
2017 August | 23 | 9 | 32 |
2017 July | 24 | 19 | 43 |
2017 June | 35 | 13 | 48 |
2017 May | 36 | 20 | 56 |
2017 April | 40 | 12 | 52 |
2017 March | 20 | 25 | 45 |
2017 February | 21 | 24 | 45 |
2017 January | 29 | 22 | 51 |
2016 December | 70 | 11 | 81 |
2016 November | 91 | 21 | 112 |
2016 October | 93 | 18 | 111 |
2016 September | 142 | 8 | 150 |
2016 August | 223 | 7 | 230 |
2016 July | 188 | 17 | 205 |
2016 June | 136 | 0 | 136 |
2016 May | 133 | 0 | 133 |
2016 April | 111 | 0 | 111 |
2016 March | 86 | 0 | 86 |
2016 February | 108 | 0 | 108 |
2016 January | 120 | 0 | 120 |
2015 December | 124 | 0 | 124 |
2015 November | 87 | 0 | 87 |
2015 October | 82 | 0 | 82 |
2015 September | 76 | 0 | 76 |
2015 August | 77 | 0 | 77 |
2015 July | 63 | 0 | 63 |
2015 June | 46 | 0 | 46 |
2015 May | 43 | 0 | 43 |
2015 April | 6 | 0 | 6 |